A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2018
Price : $35 *
At a glance
- Drugs YHP 1701 (Primary)
- Indications Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Yuhan
- 06 Sep 2018 Status changed from recruiting to completed.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.
- 11 Apr 2017 New trial record